Education
About Us
Working with TipRanks
Follow Us
Vericel Corp (DE:ATQP)
FRANKFURT:ATQP
ATQP Stock Chart & Stats
Day’s Range― - ―
52-Week Range€25.40 - €59.50
Previous CloseN/A
Volume0.00
Average Volume (3M)10.00
Market Cap
$1.31B
Enterprise Value€2.13B
Total Cash (Recent Filing)$116.88M
Total Debt (Recent Filing)$101.54M
Price to Earnings (P/E)227.6
Beta0.45
Next Earnings
Nov 06, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding50,460,205
10 Day Avg. Volume0
30 Day Avg. Volume10
Financial Highlights & Ratios
PEG Ratio-0.63
Price to Book (P/B)9.19
Price to Sales (P/S)11.31
P/FCF Ratio-461.58
Enterprise Value/Market Cap1.63
Enterprise Value/Revenue8.54
Enterprise Value/Gross Profit11.62
Enterprise Value/Ebitda131.44
Forecast
1Y Price Target
$47.28Price Target Upside80.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Growth PotentialMACI is expected to become a billion-dollar franchise, indicating strong potential for growth.
Product DevelopmentFDA clearance for the Phase 3 MASCOT study with MACI ankle indicates progress in product development and potential future opportunities.
Revenue GrowthBetter-than-expected 2Q results should set the stage for a strong second half of 2025 for VCEL, which is expected to see revenue growth acceleration from new product offerings and continued delivery on profitability.
Bears Say
Performance ChallengesVCEL shares are down approximately 42% year-to-date following two softer quarters, indicating performance challenges.
Revenue ExpectationsDespite favorable conversion dynamics and ASP increases, MACI revenue growth is expected to be steady mid-to-high teens, which might not meet higher Street estimates.
Surgeon AdoptionAround 60% of surgeons surveyed expect no change to MACI volumes despite Arthro as an option, suggesting limited impact on growth from new product offerings.
Vericel News
ATQP FAQ
What was Vericel Corp’s price range in the past 12 months?
Vericel Corp lowest stock price was €25.40 and its highest was €59.50 in the past 12 months.
What is Vericel Corp’s market cap?
Vericel Corp’s market cap is $1.31B.
When is Vericel Corp’s upcoming earnings report date?
Vericel Corp’s upcoming earnings report date is Nov 06, 2025 which is in 41 days.
How were Vericel Corp’s earnings last quarter?
Vericel Corp released its earnings results on Jul 31, 2025. The company reported -€0.009 earnings per share for the quarter, beating the consensus estimate of -€0.027 by €0.019.
Is Vericel Corp overvalued?
According to Wall Street analysts Vericel Corp’s price is currently Undervalued.
Does Vericel Corp pay dividends?
Vericel Corp does not currently pay dividends.
What is Vericel Corp’s EPS estimate?
Vericel Corp’s EPS estimate is >-0.01.
How many shares outstanding does Vericel Corp have?
Vericel Corp has 50,460,205 shares outstanding.
What happened to Vericel Corp’s price movement after its last earnings report?
Vericel Corp reported an EPS of -€0.009 in its last earnings report, beating expectations of -€0.027. Following the earnings report the stock price went up 4.678%.
Which hedge fund is a major shareholder of Vericel Corp?
Currently, no hedge funds are holding shares in DE:ATQP
Vericel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.28 (80.47% Upside)
$47.28 (80.47% Upside)
Blogger Sentiment
Bullish
DE:ATQP Sentiment 70%
Sector Average 73%
Sector Average 73%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.48%
12-Months-Change
Fundamentals
Return on Equity
2.59%
Trailing 12-Months
Asset Growth
15.60%
Trailing 12-Months
Company Description
Vericel Corp
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
ATQP Company Deck
ATQP Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance with significant revenue growth across key segments and robust profitability metrics. Despite a few challenges such as Epicel cancellations and adjusted guidance for Burn Care, the overall business outlook remains positive with promising growth indicators, especially in the MACI segment.View all DE:ATQP earnings summariesATQP Stock 12 Month Forecast
Average Price Target
€47.28
▲(80.47% Upside)
Technical Analysis
Options Prices
Currently, No data available
---